NCT00328770View on ClinicalTrials.gov

De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 1996

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Liver Carcinoma
Interventions
DRUG

Sirolimus

Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l

Trial Locations (1)

T6G 2B7

University of Alberta, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT00328770 - De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter